rxponder: chemotherapy and endocrine therapy in hr /her2- breast cancer
Published 4 weeks ago • 58 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
2:50
rxponder: sparing chemotherapy in node-positive early-stage breast cancer
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
0:38
rxponder: 21-gene assay informs chemotherapy benefit in hr node-positive breast cancer
-
1:33
anti-müllerian hormone as a predictor of chemotherapy response in hr /her2- breast cancer
-
3:08
rxponder: sparing chemotherapy in node-positive early-stage breast cancer
-
1:56
optimizing adjuvant treatment in hr /her2- early breast cancer
-
1:41
adapt trial: endocrine ribociclib vs. chemotherapy in hr /her2- early breast cancer
-
1:19
optimizing adjuvant therapy: chemotherapy necessity in hr-positive breast cancer
-
2:14
management of premenopausal hr /her2- breast cancer with micro-metastasis
-
8:18
endocrine therapy in premenopausal women with hr breast cancer
-
2:30
monarche: abemaciclib and adjuvant endocrine therapy for high-risk hr early breast cancer
-
4:13
genomic predictors for treatment selection in er breast cancer: tailorx, mindact, and rxponder
-
1:47
can we decrease chemotherapy in ln premenopausal women based on genomic tests?
-
2:05
important considerations in the management of hr , her2-negative early breast cancer
-
2:37
sabcs 2020: endocrine combination therapy & adjuvant chemotherapy in node-positive patients
-
0:54
treatment de-escalation in premenopausal patients with hr /her2- breast cancer and micro-metastasis
-
3:35
the benefits of adjuvant cdk4/6 and parp inhibition in breast cancer
-
2:49
procure: genomic signatures and adjuvant chemotherapy for breast cancer in europe
-
1:49
early breast cancer: do we need chemotherapy in low genomic/high clinical risk (er /her2-)?